FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 2021 [Available from: Aggarwal R, Vaduganathan M, Chiu N, Bhatt DL
Loop diuretics, thiazides, potassium-sparing agents, and SGLT2 inhibitors all qualify
Comprehensive toxicology evaluations reveal that the compound does not affect food intake, body temperature regulation, or basic physiological parameters at effective doses in animal models, indicating that its metabolic effects occur through specific pathway modulation rather than general physiological disruption
The development of safe and effective pharmacological agents for obesity has encountered significant challenges, marked by the emergence and subsequent decline of many medications due to adverse side effects, such as cardiovascular risk (12, 13)
doi:10.1016/j.scitotenv.2019.05.018